Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY(2019)
Abstract
To provide additional long-term safety and efficacy data in adults with moderate-to-severe atopic dermatitis (AD). We present a first-step-analysis from an ongoing phase 3, multi-center, open-label trial (NCT01949311) of subcutaneous dupilumab, 300mg weekly up to 3 years, in adults with moderate-to-severe AD. Patients are eligible after participating in previous dupilumab trials (including unexposed/interrupted/continuous treatment between the previous and this study). Outcomes include safety and Week 52 (W52) efficacy relative to baseline of the parent study. 1491 patients (60% male, mean age[SD] 39.7[13.41]) were treated; 106 withdrew from treatment. Duration-adjusted analyses showed 420.4 adverse events (AEs)/100 patient-years (100PY), 8.5 serious AEs/100PY, 27 (1.8%) treatment discontinuations due to AEs, and no deaths; most common AEs (preferred term): nasopharyngitis (20.5%), upper respiratory tract infection (9.5%), exacerbation of AD (8.2%); conjunctivitis AEs (all etiologies) occurred in 10.7% of patients. W52 analyses (N=459, 399 completed/60 patients withdrew before W52) showed 393.2 AEs/100PY, 7.6 serious AEs/100PY and 15 (3.3%) discontinuations due to AEs; most common AEs: nasopharyngitis (29.2%), headache (10.7%), upper respiratory tract infection (8.3%). At W52, 48.6% patients had an Investigator’s Global Assessment 0-1 and 75.4% achieved ≥75% reductions in Eczema Area and Severity Index (missing values as non-responders for both outcomes); pruritus Numerical Rating Scale scores decreased by 62.24% (calculated based on observed values). Efficacy did not differ among unexposed patients or interrupted/continuous transitions from parent studies. In this long-term open-label study, dupilumab showed sustained efficacy in reducing signs and symptoms improving skin lesions and pruritus among AD patients without any major safety issues.
MoreTranslated text
Key words
Dupilumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined